Papers

3

Total Citations

135

H-Index

3

About

Dr. Nicolas Zhou is a leading thoracic surgeon and researcher whose work sits at the intersection of surgical oncology, immunotherapy, and health services research. His most impactful contributions center on optimizing multimodal treatment for non-small cell lung cancer (NSCLC), particularly through the integration of neoadjuvant immunotherapy. In a landmark 2022 study, Zhou demonstrated that combining nivolumab with ipilimumab before surgery yields promising pathological responses in NSCLC patients, a finding that has garnered 94 citations and helped shape evolving perioperative protocols. He has also advanced the field of minimally invasive thoracic surgery, publishing a pivotal 2021 analysis of robotic-assisted anatomic segmentectomy that tracked national trends and patient selection criteria. Beyond technical innovation, Zhou investigates patient-centered outcomes, as evidenced by his 2023 study on surgical approach and persistent opioid use among Medicare beneficiaries undergoing lung cancer resection. With a growing bibliography that bridges cutting-edge immunotherapy, precision surgery, and real-world outcomes, Zhou is recognized as a thoughtful voice in the next generation of thoracic oncology research.

Research Focus

Key Achievements

3
H-Index
3
Papers
135
Total Citations
45
Avg Citations/Paper
🏆 Most Cited Paper
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer
94 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 27
🏛 Institutions: The University of Texas MD Anderson Cancer Center

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago